Dr. Yongkun Sun 孙永琨
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and immunotherapy for digestive system tumors and urogenital (male) system tumors.
Dr. Sun is a Chief Physician in medical oncology with extensive clinical experience. The doctor emphasizes combining evidence-based medicine with individualized treatment. Dr. Sun has significant experience in chemotherapy, targeted therapy, and immunotherapy for digestive and male urogenital system tumors. Dr. Sun leads and participates in multiple Phase I–III clinical trials of new anti-tumor drugs.
Name order: in Chinese the family name comes first (Sun Yongkun). Papers usually list the name as Yongkun Sun or Sun Y.
Selected publications
82 papers on PubMed matched by name and affiliation; 24 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Enhanced survival in resectable duodenal adenocarcinoma with adjuvant chemotherapy: evidence from a retrospective study. PubMed 42130629
- Signal Transduct Target Ther, 2026 (senior author): Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study. PubMed 41956997
- Pain Manag Nurs, 2025 (senior author): Central vs. Peripheral Venous Oxaliplatin Administration and Chemotherapy-Induced Peripheral Neuropathy Severity. PubMed 40695655
- Drug Des Devel Ther, 2025 (senior author): Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study. PubMed 41306942
- BMC Gastroenterol, 2025 (senior author): Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma. PubMed 40247200
- World J Gastroenterol, 2025 (senior author): NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer. PubMed 40124268
- Br J Cancer, 2024 (senior author): Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study. PubMed 39448860
- Front Endocrinol (Lausanne), 2024 (senior author): Survival prediction in peritoneal mesothelioma: a nomogram based on SEER data and a Chinese cohort. PubMed 39309108
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion